GlobeNewswire

Gaming Standards Association (GSA) Launches Blockchain Committee, Elects Earle G. Hall Chair

Dela

Committee Addressing Key Issues Relating to Data Sharing and Security

LAS VEGAS, April 02, 2018 (GLOBE NEWSWIRE) -- The Gaming Standards Association (GSA) has officially launched its new Blockchain Committee and has elected Earle G. Hall, CEO of AxesNetwork, as committee chair.

GSA and GSA Europe announced the committee's formation during ICE Totally Gaming. The committee's charter has been approved and the committee has slated its next meeting for this coming April 10 in London, hosted by GSA member company Playtech.

GSA President Peter DeRaedt said, "We are very excited to evolve this committee into a significantly beneficial asset to our prestigious membership. The blockchain technology is poised to change our industry forever. We are very thankful to have someone with the vision, in-depth knowledge and exceptional drive that Earle brings to GSA. He will lead us into this new realm of technology that will affect every aspect of our evolution."

Blockchain Committee Chair Earle G. Hall said, "Blockchain is the answer to so many of our inefficiencies. It is inherently designed for transparent, secure and distributed information flow. Blockchain will exponentially increase the potential for collaboration, efficiency and connectivity. I am very grateful to the membership for their vote of confidence with respect to my nomination. I am excited to pool together all the talent I can to serve our members in this need to embrace this revolution."

Blockchain technology is poised to revolutionize data sharing, security and has the ability to provide regulatory authorities with previously unobtainable levels of transparency. GSA's new Blockchain Technical Committee will collaboratively address the technology and advise on possible areas where standards could be developed. Amongst the critical initial topics to evolve are reference architecture studies, authentication methodologies, external interface compatibility and the impact on and potential for central monitoring systems.

GSA standards are created through collaboration between volunteer representatives of its members and are in use around the world, driving the industry to innovation and growth. Over the past 20 years, more than 1,600 volunteers from more than 190 companies have contributed their expertise to create 15 GSA standards in nine committees.

There is a level of membership for every type of company. Is your organization interested in working with GSA on the creation of future standards? Please join us - visit www.gamingstandards.com to learn more, and follow GSA on LinkedInTwitter, and Facebook.

GSA Platinum members include: Aristocrat Technologies Inc.; International Game Technology (IGT); Konami Gaming Inc.; Microgaming Software Systems, LTD.; NOVOMATIC Gaming Industries GmbH; Playtech, (PTEC.L) & Scientific Games International (SGMS).

Other members include: Ainsworth Game Technology Inc.; Amatic Industries GmbH; AmTote International; APEX pro gaming; Appolonia; Ares Way; Aruze Gaming America, Inc.; Atlantic Lottery Corporation; AxesNetwork Solutions Inc.; BHGLS Pty. Ltd.; BMM Testlabs; Canadian Bank Note Company, Limited; Casinos Austria; ComTrade Gaming; Combination AB; Crane Payment Innovations (CPI); DRGT Europe; eBet Gaming Systems Pty., Ltd.; European Casino Association; Everi; Fortunet; Foxwoods Resort Casino; Gamblit Gaming, LLC; Gaming Laboratories International, LLC. (GLI); Gaming Consultants International; Gaming Technologies Association; Gauselman GmbH; Ganlot; Grand Vision Gaming; House Advantage; Intralot S.A. (INLr.AT); Inspired Gaming Group Ltd.; Interblock USA; JCM Global; Loto-Québec; Macao Polytechnic Institute; Macau Gaming Equipment Manufacturers Association; Manitoba Liquor & Lotteries Corporation; Maxgaming; Mobile Gaming Monitoring On GmbH; Multi-State Lottery Association; Nidec Sankyo Corporation; Oregon Lottery; Paltronics Australasia Pty. Ltd.; Radical Blue Gaming; Random Consulting; Sega Sammy Creation, Inc.; Seminole Tribe of Florida; Seoul National University of Science & Technology; Smernax Holdings Ltd.; Sightline Payments; Spintec d.o.o.; Synergy Blue; techno-consult GmbH; U1 Gaming; TNDR, Inc.; Universal de Desarrollos Electronicos, S.A.; UNLV International Gaming Institute; VEIKKAUS; Western Canada Lottery Corporation; Wojskowe Zaklady Lacznosci Nr 1 S.A.

CONTACT:
Peter DeRaedt
Gaming Standards Association 
President
Tel: +1 (775) 846-4422
E-mail: pdr@gamingstandards.com 

Paul Speirs-Hernandez
Steinbeck Communications 
President
+1 (702) 413-4278
paul@steinbeckcommunications.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gaming Standards Association via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum